Study characteristics by final cognitive diagnosis for individuals with NCI or MCI at baseline
| NCI (N=212) | MCI (N=160) | AD (N=178) | Other dementia (N=9) | |
| Gender | ||||
| Female | 148 (69.8%) | 100 (62.5%) | 133 (74.7%) | 5 (55.6%) |
| Male | 64 (30.2%) | 60 (37.5%) | 45 (25.3%) | 4 (44.4%) |
| Education (years) | ||||
| Mean (SD) | 15.5 (3.6) | 15.5 (3.1) | 15.3 (3.2) | 16.0 (3.8) |
| Median (min, max) | 16.0 (7.0, 27.0) | 16.0 (5.0, 25.0) | 16.0 (8.0, 28.0) | 16.0 (12.0, 24.0) |
| Age at diagnosis | ||||
| Mean (SD) | – | – | 88.8 (6.1) | 84.0 (5.9) |
| Median (min, max) | – | – | 88.9 (71.4, 106) | 84.4 (74.6, 91.7) |
| Missing | – | – | 12 (6.7%) | 3 (33.3%) |
| Age at death | ||||
| Mean (SD) | 88.1 (6.5) | 89.8 (5.9) | 91.8 (5.7) | 86.9 (5.9) |
| Median (min, max) | 88.5 (71.3, 103) | 90.2 (72.1, 104) | 92.3 (76.0, 106) | 85.9 (77.3, 95.9) |
| APOE genotype | ||||
| E23 | 43 (20.3%) | 14 (8.8%) | 20 (11.2%) | 2 (22.2%) |
| E33 | 143 (67.5%) | 114 (71.3%) | 115 (64.6%) | 3 (33.3%) |
| E34 | 26 (12.3%) | 32 (20.0%) | 43 (24.2%) | 4 (44.4%) |
| Global AD pathology score | ||||
| Mean (SD) | 0.5 (0.5) | 0.7 (0.6) | 0.9 (0.6) | 0.7 (0.4) |
| Median (min, max) | 0.3(0, 2.6) | 0.6(0.0, 2.3) | 0.8(0.0, 2.8) | 0.8(0.0, 1.4) |
| Beta-amyloid score | ||||
| Mean (SD) | 3.4 (4.0) | 4.7 (4.6) | 6.5 (4.8) | 7.4 (6.9) |
| Median (min, max) | 1.5(0, 22.9) | 3.5(0, 17.9) | 6.0(0, 19.9) | 8.4(0.0, 17.0) |
| Missing | 2 (0.9%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Neurofibrillary tangle score | ||||
| Mean (SD) | 3.5 (4.0) | 5.6 (5.9) | 9.3 (8.5) | 2.6 (1.9) |
| Median (min, max) | 2.6 (0.0, 27.3) | 4.1 (0.0, 38.2) | 6.9 (0.0, 42.8) | 2.5 (0.5, 5.9) |
| Missing | 2 (0.9%) | 0 (0%) | 1 (0.6%) | 0 (0%) |
| Modified CERAD | ||||
| Definite AD | 37 (17.5%) | 44 (27.5%) | 74 (41.6%) | 2 (22.2%) |
| Probable AD | 62 (29.2%) | 64 (40.0%) | 79 (44.4%) | 5 (55.6%) |
| Possible AD | 26 (12.3%) | 17 (10.6%) | 6 (3.4%) | 0 (0%) |
| No AD | 87 (41.0%) | 35 (21.9%) | 19 (10.7%) | 2 (22.2%) |
| Braak stage | ||||
| 0–II | 49 (23.1%) | 27 (16.9%) | 13 (7.3%) | 0 (0%) |
| III–IV | 147 (69.3%) | 99 (61.9%) | 90 (50.6%) | 9 (100%) |
| V–VI | 16 (7.5%) | 34 (21.3%) | 75 (42.1%) | 0 (0%) |
| Cerebral amyloid angiopathy | ||||
| 0 | 66 (31.1%) | 39 (24.4%) | 31 (17.4%) | 3 (33.3%) |
| 1 | 96 (45.3%) | 74 (46.3%) | 79 (44.4%) | 4 (44.4%) |
| 2 | 33 (15.6%) | 33 (20.6%) | 47 (26.4%) | 1 (11.1%) |
| 3 | 16 (7.5%) | 14 (8.8%) | 21 (11.8%) | 1 (11.1%) |
| Missing | 1 (0.5%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Cerebral atherosclerosis stage | ||||
| 0 | 66 (31.1%) | 43 (26.9%) | 27 (15.2%) | 1 (11.1%) |
| 1 | 96 (45.3%) | 72 (45.0%) | 86 (48.3%) | 2 (22.2%) |
| 2 | 38 (17.9%) | 36 (22.5%) | 50 (28.1%) | 5 (55.6%) |
| 3 | 12 (5.7%) | 9 (5.6%) | 15 (8.4%) | 1 (11.1%) |
| Gross cerebral infarctions | ||||
| Not present | 132 (62.3%) | 96 (60.0%) | 86 (48.3%) | 3 (33.3%) |
| Present | 80 (37.7%) | 64 (40.0%) | 92 (51.7%) | 6 (66.7%) |
| Hippocampal sclerosis | ||||
| Not present | 208 (98.1%) | 155 (96.9%) | 151 (84.8%) | 8 (88.9%) |
| Present | 4 (1.9%) | 5 (3.1%) | 27 (15.2%) | 1 (11.1%) |
| Lewy bodies | ||||
| Not present | 173 (81.6%) | 124 (77.5%) | 115 (64.6%) | 5 (55.6%) |
| Present | 34 (16.0%) | 29 (18.1%) | 56 (31.5%) | 4 (44.4%) |
| Missing | 5 (2.4%) | 7 (4.4%) | 7 (3.9%) | 0 (0%) |
| Microinfarcts | ||||
| Not present | 134 (63.2%) | 105 (65.6%) | 105 (59.0%) | 5 (55.6%) |
| Present | 78 (36.8%) | 55 (34.4%) | 73 (41.0%) | 4 (44.4%) |
| TDP-43 staging | ||||
| 0 | 125 (59.0%) | 81 (50.6%) | 65 (36.5%) | 6 (66.7%) |
| 1 | 46 (21.7%) | 33 (20.6%) | 29 (16.3%) | 2 (22.2%) |
| 2 | 29 (13.7%) | 31 (19.4%) | 46 (25.8%) | 1 (11.1%) |
| 3 | 7 (3.3%) | 14 (8.8%) | 38 (21.3%) | 0 (0%) |
| Missing | 5 (2.4%) | 1 (0.6%) | 0 (0%) | 0 (0%) |
| HDL-C (mmol/L) | ||||
| Mean (SD) | 1.47 (0.442) | 1.48 (0.462) | 1.46 (0.418) | 1.18 (0.270) |
| Median (Min, Max) | 1.40 (0.518, 2.88) | 1.42 (0.674, 2.67) | 1.40 (0.725, 3.73) | 1.30 (0.725, 1.50) |
| LDL-C (mmol/L) | ||||
| Mean (SD) | 2.65 (0.833) | 2.73 (0.850) | 2.80 (0.871) | 2.99 (0.972) |
| Median (min, max) | 2.59 (0.648, 4.87) | 2.66 (1.06, 6.06) | 2.73 (0.933, 5.41) | 3.01 (1.37, 4.77) |
| TG (mmol/L) | ||||
| Mean (SD) | 1.67 (0.800) | 1.58 (0.774) | 1.56 (0.755) | 1.88 (0.700) |
| Median (min, max) | 1.51 (0.542, 4.22) | 1.37 (0.440, 4.28) | 1.37 (0.474, 4.28) | 1.91 (0.926, 3.09) |
| Lipid lowering treatment | ||||
| Not present | 130 (61.3%) | 108 (67.5%) | 118 (66.3%) | 8 (88.9%) |
| Present | 82 (38.7%) | 52 (32.5%) | 60 (33.7%) | 1 (11.1%) |
AD, Alzheimer’s disease; CERAD, Consortium to Establish a Registry for Alzheimer’s Disease; HDL-C, high-density lipoprotein cholesterol; MCI, mild cognitive impairment; NCI, no cognitive impairment; TG, triglycerides.